全文获取类型
收费全文 | 49254篇 |
免费 | 5426篇 |
国内免费 | 1454篇 |
专业分类
耳鼻咽喉 | 230篇 |
儿科学 | 1180篇 |
妇产科学 | 402篇 |
基础医学 | 16114篇 |
口腔科学 | 579篇 |
临床医学 | 3658篇 |
内科学 | 8276篇 |
皮肤病学 | 1456篇 |
神经病学 | 1818篇 |
特种医学 | 2539篇 |
外国民族医学 | 12篇 |
外科学 | 3242篇 |
综合类 | 5725篇 |
现状与发展 | 15篇 |
预防医学 | 2157篇 |
眼科学 | 385篇 |
药学 | 3286篇 |
9篇 | |
中国医学 | 1428篇 |
肿瘤学 | 3623篇 |
出版年
2024年 | 108篇 |
2023年 | 766篇 |
2022年 | 1333篇 |
2021年 | 1955篇 |
2020年 | 1710篇 |
2019年 | 1973篇 |
2018年 | 2062篇 |
2017年 | 1852篇 |
2016年 | 1808篇 |
2015年 | 1983篇 |
2014年 | 2857篇 |
2013年 | 3295篇 |
2012年 | 2574篇 |
2011年 | 2953篇 |
2010年 | 2344篇 |
2009年 | 2185篇 |
2008年 | 2259篇 |
2007年 | 2141篇 |
2006年 | 1944篇 |
2005年 | 1675篇 |
2004年 | 1639篇 |
2003年 | 1513篇 |
2002年 | 1210篇 |
2001年 | 1117篇 |
2000年 | 952篇 |
1999年 | 859篇 |
1998年 | 922篇 |
1997年 | 854篇 |
1996年 | 745篇 |
1995年 | 763篇 |
1994年 | 785篇 |
1993年 | 673篇 |
1992年 | 421篇 |
1991年 | 349篇 |
1990年 | 349篇 |
1989年 | 274篇 |
1988年 | 231篇 |
1987年 | 168篇 |
1986年 | 149篇 |
1985年 | 360篇 |
1984年 | 376篇 |
1983年 | 242篇 |
1982年 | 300篇 |
1981年 | 246篇 |
1980年 | 185篇 |
1979年 | 175篇 |
1978年 | 112篇 |
1977年 | 102篇 |
1976年 | 115篇 |
1975年 | 69篇 |
排序方式: 共有10000条查询结果,搜索用时 14 毫秒
21.
《Journal of pharmaceutical sciences》2019,108(11):3521-3523
We make the case for why continuous pharmaceutical manufacturing is essential, what the barriers are, and how to overcome them. To overcome them, government action is needed in terms of tax incentives or regulatory incentives that affect time. 相似文献
22.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献23.
《The Journal of emergency medicine》2020,58(5):785-796
BackgroundBacteremia causes a major worldwide burden, in terms of financial and productivity costs, as well the morbidity and mortality it can ultimately cause. Proper treatment of bacteremia is a challenge because of the species-dependent response to antibiotics. The T2Bacteria Panel is a U.S. Food and Drug Administration–cleared and culture-independent assay for detection of bacteremia, including common ESKAPE pathogens—Escherichia coli, Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, and Pseudomonas aeruginosa—and provides species identification in as little as 3.6 h directly from blood.ObjectiveOur aim was to evaluate the T2Bacteria assay performance and potential to affect patient care in the emergency department (ED).MethodsED patients from a Louisiana and Florida center were enrolled as part of the T2Bacteria Panel clinical study, which was prospective and noninterventional. Blood samples for blood culture (BC) and T2Bacteria were matched in time and anatomic location.ResultsData from 137 ED patients were evaluated. Relative to BC, T2Bacteria showed 100% positive percent agreement and 98.4% negative percent agreement. In addition, for species on the T2Bacteria Panel, the T2Bacteria assay detected 25% more positives associated with infection, and on average identified the infectious species 56.6 h faster. The T2Bacteria assay covered 70.5% of all species detected by BC. Finally, relative to actual care, the T2Bacteria assay could have potentially focused therapy in 8 patients, reduced time to a species-directed therapy in 4 patients, and reduced time to effective therapy in 4 patients.ConclusionsIn this ED population, the T2Bacteria assay was a rapid and sensitive detector of bacteremia from common ESKAPE pathogens and showed the theoretical potential to influence subsequent patient therapy, ranging from antibiotic de-escalation to faster time to effective therapy. 相似文献
24.
《Cancer cell》2021,39(11):1497-1518.e11
25.
《Vaccine》2016,34(24):2663-2670
Human metapneumovirus (HMPV) is a major cause of morbidity and mortality from acute lower respiratory tract illness, with most individuals seropositive by age five. Despite the presence of neutralizing antibodies, secondary infections are common and can be severe in young, elderly, and immunocompromised persons. Preclinical vaccine studies for HMPV have suggested a need for a balanced antibody and T cell immune response to enhance protection and avoid lung immunopathology. We infected transgenic mice expressing human HLA-A*0201 with HMPV and used ELISPOT to screen overlapping and predicted epitope peptides. We identified six novel HLA-A2 restricted CD8+ T cell (TCD8) epitopes, with M39–47 (M39) immunodominant. Tetramer staining detected M39-specific TCD8 in lungs and spleen of HMPV-immune mice. Immunization with adjuvant-formulated M39 peptide reduced lung virus titers upon challenge. Finally, we show that TCD8 from HLA-A*0201 positive humans recognize M39 by IFNγ ELISPOT and tetramer staining. These results will facilitate HMPV vaccine development and human studies. 相似文献
26.
27.
《Diabetes & Metabolic Syndrome: Clinical Research & Reviews》2019,13(6):3105-3112
Diabetes is on the rise in India and recently shown to be increasing in the urban underprivileged. Lack of awareness of the disease, its complications, combined with lack of financial resources among the underprivileged, often results in late detection and more complications in them. To combat this, healthcare delivered at the doorstep through the use of a customised mobile medical van is a potentially attractive option.We used a customized mobile van (included trained personnel, glucose meters, fundus evaluation camera, apparatus for detection of neuropathy and foot circulation and net enabled Skype calling for remote consultation) for educating general population regarding healthy lifestyle and screening, management and intervention in patients with diabetes.The project covered 10 underprivileged areas (n, 2,31,000 people) in Delhi. Total of 24,072 individuals (10.9% of total population) attended 352 awareness sessions. A total 3,12,347 visits (included repeat visits) were carried out for screening, education and management for obesity and diabetes. During screening (n, 16,834), 2933 subjects (18.7%) had high random blood glucose levels (>200 mg/dL) and had a blood pressure averaging 127.1 ± 23.6/81.3 ± 16.6 mm of mercury (n, 16,339). A pre-post intensive lifestyle counselling for 6 months in a subset of 352 diabetic patients (of which 77.8% i.e. n, 274 were overweight/obese) showed a significant lowering in weight (p < 0.001). In addition, 292 frontline workers and 256 paramedical workers were given training regarding lifestyle and diabetes, over 20 sessions.Based on achievements of this project of spreading awareness, screening, and management of diabetes and obesity in the large number of individuals in urban underprivileged colony, we believe this project could be extended to other cities and rural areas of India, and to other developing countries as well. 相似文献
28.
29.
目的 探讨中性粒细胞与淋巴细胞比值(neutrophil to lymphocyte ratio,NLR)对三阴性乳腺癌的临床预后影响及与Ki - 67表达的关系。方法 回顾性分析2006年1月 - 2012年12月于我院乳腺外科住院治疗的134例三阴性乳腺癌患者。NLR最佳临床分界值采用ROC曲线确定,并依此分NLR<2.64组和NLR≥2.64组。临床独立预后因素采用单因素和多因素Cox回归模型分析。术后生存时间和生存曲线比较采用Kaplan - Meier和log - rank方法。Ki - 67的表达采用免疫组织化学方法检测。结果 NLR是三阴性乳腺癌的独立预后因素,最佳临界值为2.64。NLR<2.64组术后中位DFS为39.10月,中位OS为52.30月;NLR≥2.64组术后中位DFS为27.35月,中位OS为37.35月。2组术后DFS和OS比较,差异具有统计学意义(P<0.05)。NLR低组伴Ki - 67表达阴性的三阴性患者术后中位DFS和OS生存时间显著高于其他情况。结论 NLR是三阴性乳腺癌的关键影响预后因素,具有重复性强、非侵袭性、方便实用等特性,可用于预测三阴性乳腺癌临床预后。 相似文献
30.